Emerging targeted drug delivery strategies toward ovarian cancer

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Ovarian cancer presents a high mortality rate, with conventional chemotherapy often failing due to drug resistance, metastasis, or severe adverse effects.
• Existing treatments struggle with efficacy in advanced, metastatic, or drug-resistant ovarian cancer cases.

Purpose of the Study:

• To review recent advancements in targeted drug delivery strategies for ovarian cancer.
• To highlight approaches that enhance chemotherapy and molecular therapy efficacy.
• To focus on overcoming challenges in advanced, metastatic, relapsed, and drug-resistant ovarian cancers.

Main Methods:

• Review of targeted delivery systems including antibody-drug conjugates (ADCs), polymer-drug conjugates, and nanomedicines.
• Analysis of strategies enhancing therapeutic agent selectivity and reducing systemic toxicity.
• Exploration of how targeted delivery potentiates novel therapies like gene and photodynamic therapy.

Main Results:

• Targeted delivery systems demonstrate effectiveness in preclinical and clinical settings for ovarian cancer.
• These systems improve selectivity, bypass drug resistance mechanisms, and minimize systemic toxicity.
• Various targeted approaches, including nanomedicines and conjugates, are advancing ovarian cancer treatment.

Conclusions:

• Targeted drug delivery is crucial for improving outcomes in challenging ovarian cancer cases.
• These strategies offer a promising path for treating advanced, metastatic, and drug-resistant ovarian cancers.
• Further development of targeted delivery systems is essential for next-generation ovarian cancer therapies.